

The HA Drug Advisory Committee (DAC), comprising doctors, clinical pharmacologists and pharmacists, systematically appraises new drugs every three months. DAC is supported by expert panels which provide specialist views on the selection of drugs for individual specialties.

Drug Advisory Committee Jan 2021 Meeting Outcome

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection ¹
1	Arsenic Trioxide	Arsenol	Malignant disease and immunosuppression	Approved	
2	Atezolizumab	Tecentriq	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
3	Baloxavir	Xofluza	Infections	Rejected	Alternative(s) available in HADF with comparable benefits
4	Bilastine	Labixten	Respiratory system	Rejected	Alternative(s) available in HADF with comparable benefits
5	Brexpiprazole	Rexulti	Central nervous system	Approved	
6	Brodalumab	Lumicef	Skin	Rejected	Alternative(s) available in HADF with comparable benefits
7	Cladribine	Mavenclad	Malignant disease and immunosuppression	Approved	
8	Dacomitinib	Vizimpro	Malignant disease and immunosuppression	Rejected	Alternative(s) available in HADF with comparable benefits
9	Emicizumab	Hemlibra	Cardiovascular system	Approved	
10	Entrectinib	Rozlytrek	Malignant disease and immunosuppression	Rejected	Insufficient evidence to demonstrate significant clinical outcome benefits
11	Fentanyl citrate	PecFent	Central nervous system	Rejected	Alternative(s) available in HADF with comparable benefits
12	Gemtuzumab Ozogamicin	Mylotarg	Malignant disease and immunosuppression	Pending	Pending further information
13	Lisdexamfetamine	Vyvanse	Central nervous system	Approved	
14	Niraparib	Zejula	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
15	Polatuzumab vedotin	Polivy	Malignant disease and immunosuppression	Rejected	The justification of the treatment's cost in relation to its benefits is insufficient
16	Ranibizumab	Lucentis	Eye	Rejected	Alternative(s) available in HADF with comparable benefits
17	Rituximab	Rixathon	Malignant disease and immunosuppression	Approved	
18	Sirolimus	Rapamune	Malignant disease and immunosuppression	Approved	
19	Tisagenlecleucel	Kymriah	Malignant disease and immunosuppression	Approved	

	Generic name	Brand name	Therapeutic Class	Meeting outcome	Primary reason for rejection¹
20	Tocilizumab	Actemra	Musculoskeletal and joint disease	Approved	
21	Trastuzumab	Herzuma	Malignant disease and immunosuppression	Approved	

¹ The evaluation embraces the principles of safety, efficacy and cost-effectiveness and takes into account other relevant factors, including international recommendations and practices, advance in technology, disease state, patient compliance, quality of life, actual experience in the use of drugs as well as views of professionals and patients groups.